Global Antisense & Rnai Therapeutics Industry: Key Statistics and Insights in 2024-2032
Summary:
- The global antisense & Rnai therapeutics market size reached USD 1.7 Billion in 2023.
- The market is expected to reach USD 3.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.25% during 2024-2032.
- North America leads the market, accounting for the largest antisense & Rnai therapeutics market share.
- Antisense RNA accounts for the majority of the market share in the technology segment as it offers enhanced effectiveness.
- Pulmonary delivery holds the largest share in the antisense & Rnai therapeutics industry.
- On the basis of the application, the market has been classified into oncology, cardiovascular diseases (CVDs), respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and others.
- The rising funding and collaborations is a primary driver of the antisense & Rnai therapeutics market.
- The increasing prevalence of chronic and genetic diseases and advancements in genomic research are reshaping the antisense & Rnai therapeutics market.
Request for a sample copy of this report: https://www.imarcgroup.com/antisense-rnai-therapeutics-market/requestsample
Industry Trends and Drivers:
- Increasing Funding and Collaborations:
The growing demand for antisense and Rnai therapeutics on account of the rising funding and collaborations is offering a favorable market outlook. Pharmaceutical companies, biotech firms, and academic institutions are pooling resources and expertise to accelerate the development of RNA-based therapies. The increasing funding from public and private sectors, including venture capital and government grants, is impelling the market growth. Moreover, there is a rise in the number of research and clinical trials for antisense and Rnai drugs. Major pharmaceutical companies are forming strategic partnerships with biotech firms to co-develop novel therapies. These collaborations are expediting the translation of scientific discoveries into clinical applications, enhancing drug pipelines and commercialization prospects.
- Rising Prevalence of Chronic and Genetic Diseases:
The increasing prevalence of chronic diseases, such as cancer, neurodegenerative disorders, and genetic conditions, is catalyzing the demand for antisense and Rnai therapeutics. Traditional treatment methods often fail to address the root genetic causes of these diseases, leading to a growing interest in therapies that can modulate gene expression. Antisense and Rnai therapeutics offer a novel approach by targeting disease at the molecular level, enabling more effective treatments for conditions like Huntington’s disease, amyotrophic lateral sclerosis (ALS), and cardiovascular diseases. The growing demand for targeted and gene-based therapies due to the aging global population and lifestyle-related disorders among individuals is positively influencing the market.
- Advancements in Genomic Research:
Technologies like CRISPR and next-generation sequencing have enhanced scientists' understanding of gene function and mutation, enabling them to identify and target disease-causing genes more precisely. This is leading to the development of RNA-based therapies, which can selectively silence or modify gene expression to treat various diseases. The ability to design antisense oligonucleotides (ASOs) and Rnai molecules with greater specificity and fewer side effects is driving innovation in this field. Furthermore, technological advancements in gene-editing tools are supporting the integration of Rnai into broader therapeutic frameworks, expanding the range of treatable conditions. As research uncovers new therapeutic targets, the pipeline for RNA-based drugs is growing.
The antisense & rnai therapeutics market forecast offers insights into future opportunities and challenges, drawing on historical data and predictive modeling.
Antisense & Rnai Therapeutics Market Report Segmentation:
Breakup By Technology:
- RNA Interference
- siRNA
- miRNA
- Antisense RNA
Antisense RNA accounts for the majority of shares as it offers enhanced effectiveness.
Breakup By Route of Administration:
- Intravenous Route
- Subcutaneous Route
- Intrathecal Route
- Pulmonary Delivery
- Intraperitoneal Injection
- Others
Pulmonary delivery dominates the market because of its ability to enable a high concentration of the solution.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys the leading position owing to a large market for antisense & Rnai therapeutics driven by favorable government initiatives.
Top Antisense & Rnai Therapeutics Market Leaders:
The antisense & Rnai therapeutics market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:
- Alnylam Pharmaceuticals Inc.
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals Inc.
- Benitec Biopharma Ltd.
- Bio-Path Holdings Inc.
- Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
- Ionis Pharmaceuticals Inc.
- OliX Pharmaceuticals Inc.
- Phio Pharmaceuticals Corp.
- Sarepta Therapeutics Inc.
- Silence Therapeutics
- Sirnaomics Inc
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145